NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free SWTX Stock Alerts $49.95 -0.15 (-0.30%) (As of 03:39 PM ET) Add Compare Share Share Today's Range$49.62▼$52.2050-Day Range$39.50▼$52.5052-Week Range$18.00▼$53.92Volume777,252 shsAverage Volume1.19 million shsMarket Capitalization$3.69 billionP/E RatioN/ADividend YieldN/APrice Target$68.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get SpringWorks Therapeutics alerts: Email Address SpringWorks Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.1% Upside$68.00 Price TargetShort InterestBearish15.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 3 Articles This WeekInsider TradingSelling Shares$751,500 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.71) to ($3.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.56 out of 5 starsMedical Sector501st out of 938 stocksBiological Products, Except Diagnostic Industry80th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.00, SpringWorks Therapeutics has a forecasted upside of 36.1% from its current price of $49.95.Amount of Analyst CoverageSpringWorks Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.14% of the outstanding shares of SpringWorks Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in SpringWorks Therapeutics has recently increased by 0.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 2.8 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for SpringWorks Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for SWTX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $751,500.00 in company stock.Percentage Held by InsidersOnly 7.43% of the stock of SpringWorks Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($4.71) to ($3.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -9.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 4.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About SpringWorks Therapeutics Stock (NASDAQ:SWTX)SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More SWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Stock News HeadlinesMarch 26, 2024 | americanbankingnews.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Buy" by BrokeragesMarch 17, 2024 | finance.yahoo.comSWTX Apr 2024 70.000 callMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 6, 2024 | finance.yahoo.comSWTX Apr 2024 60.000 putMarch 6, 2024 | finance.yahoo.comSWTX Apr 2024 65.000 callMarch 4, 2024 | globenewswire.comSpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNFebruary 29, 2024 | globenewswire.comSpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid TumorsMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.February 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)February 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Telesis Bio (TBIO) and Springworks Therapeutics (SWTX)February 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX) and ACADIA Pharmaceuticals (ACAD)February 27, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comSpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesFebruary 24, 2024 | msn.comSpringWorks Therapeutics (SWTX) Price Target Increased by 13.30% to 62.40February 22, 2024 | finance.yahoo.comSpringWorks Therapeutics to Present at Upcoming Investor ConferencesFebruary 22, 2024 | globenewswire.comSpringWorks Therapeutics to Present at Upcoming Investor ConferencesFebruary 16, 2024 | msn.comViking Therapeutics gains amid renewed takeover speculationFebruary 7, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc Insider Sells Company SharesFebruary 6, 2024 | finance.yahoo.comSpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 SharesFebruary 3, 2024 | msn.comSpringWorks Therapeutics CDO Resigns, Assumes Advisory RoleJanuary 31, 2024 | forbes.comSerendipity And Science: Forging Billion-Dollar Oncology BreakthroughsJanuary 31, 2024 | finance.yahoo.comSpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 25, 2024 | markets.businessinsider.comWall Street Analysts Are Bullish on Top Healthcare PicksJanuary 19, 2024 | benzinga.comSpringWorks Therapeutics's Options Frenzy: What You Need to KnowJanuary 10, 2024 | msn.comTG Therapeutics prelim results see FY23 BRIUMVI U.S. revenue $89M; initiates FY24 outlookJanuary 8, 2024 | finance.yahoo.comSpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare ConferenceSee More Headlines Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees305Year Founded2017Price Target and Rating Average Stock Price Target$68.00 High Stock Price Target$75.00 Low Stock Price Target$52.00 Potential Upside/Downside+36.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,100,000.00 Net MarginsN/A Pretax Margin-5,968.50% Return on Equity-65.69% Return on Assets-57.04% Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.37 Sales & Book Value Annual Sales$5.45 million Price / Sales674.13 Cash FlowN/A Price / Cash FlowN/A Book Value$10.01 per share Price / Book4.97Miscellaneous Outstanding Shares73,790,000Free Float68,305,000Market Cap$3.67 billion OptionableOptionable Beta0.83 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Saqib Islam J.D. (Age 54)CEO & Director Comp: $1.26MMr. Francis I. Perier Jr. (Age 64)M.B.A., Chief Financial Officer Comp: $710.6kDr. Badreddin Edris Ph.D. (Age 36)Chief Operating Officer Comp: $998.61kMr. Bhavesh Ashar (Age 57)Chief Commercial Officer Comp: $729.62kMr. Michael P. Nofi (Age 53)Chief Accounting Officer Mr. Tai-An Lin Ph.D.Chief Scientific OfficerMs. Kim DiamondVice President of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)General Counsel & Secretary Comp: $568.64kMr. Daniel J. Pichl (Age 40)Chief People Officer Comp: $428.51kDr. James Cassidy M.D. (Age 64)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsArcellxNASDAQ:ACLXImmunityBioNASDAQ:IBRXApogee TherapeuticsNASDAQ:APGEIovance BiotherapeuticsNASDAQ:IOVAImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 12,690 shares on 3/27/2024Ownership: 0.017%Vanguard Group Inc.Bought 1,114,080 shares on 3/11/2024Ownership: 8.181%Wellington Management Group LLPBought 21,167 shares on 3/5/2024Ownership: 0.029%Goldman Sachs Group Inc.Sold 131,202 shares on 3/1/2024Ownership: 0.625%American International Group Inc.Bought 4,276 shares on 2/28/2024Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions SWTX Stock Analysis - Frequently Asked Questions Should I buy or sell SpringWorks Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWTX shares. View SWTX analyst ratings or view top-rated stocks. What is SpringWorks Therapeutics' stock price target for 2024? 6 brokers have issued 1-year price targets for SpringWorks Therapeutics' stock. Their SWTX share price targets range from $52.00 to $75.00. On average, they predict the company's stock price to reach $68.00 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts. How have SWTX shares performed in 2024? SpringWorks Therapeutics' stock was trading at $36.50 on January 1st, 2024. Since then, SWTX stock has increased by 36.8% and is now trading at $49.95. View the best growth stocks for 2024 here. When is SpringWorks Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our SWTX earnings forecast. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $0.20. The company earned $5.45 million during the quarter, compared to analyst estimates of $1.26 million. During the same period in the previous year, the company earned ($1.19) EPS. What ETFs hold SpringWorks Therapeutics' stock? ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI). When did SpringWorks Therapeutics IPO? SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? SpringWorks Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.65%), Vanguard Group Inc. (8.18%), Price T Rowe Associates Inc. MD (4.44%), Price T Rowe Associates Inc. MD (4.44%), Point72 Asset Management L.P. (3.46%) and Perceptive Advisors LLC (3.13%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does SpringWorks Therapeutics have any subsidiaries? The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..Read More This page (NASDAQ:SWTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.